Advertisement
Advertisement
U.S. markets open in 4 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Syneos Health, Inc. (SYNH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
70.11+1.53 (+2.23%)
At close: 04:00PM EDT
70.11 0.00 (0.00%)
After hours: 04:15PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close68.58
Open69.31
Bid0.00 x 900
Ask0.00 x 800
Day's Range69.28 - 71.36
52 Week Range66.73 - 104.18
Volume402,971
Avg. Volume818,548
Market Cap7.192B
Beta (5Y Monthly)1.84
PE Ratio (TTM)30.32
EPS (TTM)2.31
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SYNH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Syneos Health, Inc.
    SYNH: Lowering target price to $74.00SYNEOS HEALTH INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Syneos Health Leaders Recognized by HBA

    Healthcare Businesswomen’s Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry ImpactMORRISVILLE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Kasey Boynton, MPH, MBA, Director, Client Engagement, Real World Evidence & Late Phase, and Feni Komline, RN, BSN, Director, Engagement Center, Deployment Solutions, have been recognized by the Healthcare Businesswomen’

  • Zacks

    Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

    Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

  • American City Business Journals

    Syneos Health names new CEO as revenues race past $5 billion

    The company with about 28,000 employees has a new CEO following a year that saw revenues soar by double digits.

Advertisement
Advertisement